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Background
Barrett’s esophagus (BE) is the pathologic replacement of
esophageal squamous epithelium with goblet cell-lined colum-
nar tissue and intestinal metaplasia [1, 2]. A diagnosis of BE is
associated with an increased risk for progression to high grade
dysplasia (HGD), which is itself associated with a 5–20% risk of
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ABSTRACT
Background and aims The impact of the advent of an in-
stitutional endoscopic eradication therapy (EET) program
on surgical practice for Barrett’s esophagus (BE)-associated
high grade dysplasia (HGD) or suspected T1a esophageal
adenocarcinoma (EAC) is unknown. The aims of this study
are to evaluate the different endoscopic modalities used
during development of our EET program and factors asso-
ciated with the use of EET or surgery for these patients after
its development.
Methods Patients who underwent primary endoscopic or
surgical treatment for BE-HGD or early EAC at our hospital
between January 1992 and December 2014 were retrospec-
tively identified. They were categorized by their initial mod-
ality of treatment during the first year, and the impact over
time for choice of therapy was assessed by multivariable lo-
gistic regression.
Results We identified 386 patients and 80 patients who
underwent EET and surgery, respectively. EET included sin-
gle modality therapy in 254 (66%) patients and multimodal
therapy in 132 (34%) patients. Multivariable logistic regres-
sion showed that, for each subsequent study year, EET was
more likely to be performed in patients who were older (P=
0.0009), with shorter BE lengths (P<0.0001), and with a
pretreatment diagnosis of HGD (P=0.0054) compared to
surgical patients. The diagnosis of EAC did not increase the
utilization of EET compared to surgery as time progressed
(P=0.8165).
Conclusion The introduction of an EET program at our
hospital increased the odds of utilizing EET versus surgery
over time for initial treatment of patients who were older,
had shorter BE lengths or the diagnosis of BE-HGD, but not
in patients with EAC.
Original article
* Abstract and poster presentation: “Primary Endoscopic Therapy vs. Sur-
gical Management of Barrett’s Esophagus with High Grade Dysplasia or
Early Adenocarcinoma: Experience of a Tertiary Referral Center 1992–
2014.” DDW 2016, San Diego, CA, USA.
** Co-first authors.
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esophageal adenocarcinoma (EAC) [3]. EAC is associated with
high morbidity and mortality, and its increasing incidence in
the United States has prompted targeted screening and surveil-
lance programs for established BE and endoscopic eradication
therapies (EET) to treat dysplastic BE and early EAC [3–10].
EET has largely replaced surgery as the primary intervention
for BE-HGD and early adenocarcinoma (T1a), due to compar-
able 5-year survival and lower morbidity and adverse events
[11–16]. Efficacy and clinical outcomes of individual endo-
scopic therapies, such as photodynamic therapy (PDT), endo-
scopic mucosal resection (EMR), radiofrequency ablation
(RFA), and cryotherapy are generally similar; however, current
therapy with combined EMR and ablation appears to have an in-
creased response to treatment and potentially lower recurrence
compared to individual modality treatment alone [17, 18]. A re-
cent consensus statement noted that EET is an acceptable pri-
mary treatment strategy for BE-HGD or early EAC, and that
endoscopic intervention is preferred over endoscopic surveil-
lance for such patients [19]. Additionally, EET was incorporated
into National Comprehensive Cancer Network (NCCN) guide-
lines for the primary management of esophageal malignancy
in 2012 [20].
Population-based cohort studies suggest that the use of
endoscopic therapy to treat BE-HGD and early EAC has in-
creased from 1998 to 2009, with an associated decline in the
proportion of surgical cases [15, 21]. In light of these trends,
the impact of such programs on the choice of medical or surgi-
cal therapy for individual referral centers remains unknown.
With the increasing role of EET in the management of BE-asso-
ciated dysplasia, we hypothesized that the characteristics of pa-
tients treated with esophagectomy at our hospital for these in-
dications would change after the development of an EET pro-
gram. The primary aim of this study is to evaluate the impact
of the development of an EET program on the frequency of pri-
mary surgical therapy for treatment-naïve patients with BE-
HGD and early EAC and to evaluate clinical variables potentially
associated with choice of type of therapy in these patients. The
secondary aim was to evaluate the evolution of EET modalities
used at our center during the study period.
Materials and methods
Study design and patient selection
This is a retrospective, single-center study approved by the In-
stitutional Review Board at Indiana University Health Hospital in
Indianapolis, Indiana. Utilizing two departmental databases
(one surgical database with esophagectomies and one endo-
scopic database of EET for BE-associated HGD or early EAC),
we identified consecutive treatment-naïve patients 18 years or
older who underwent either primary endoscopic therapy or
surgery for BE-HGD or early EAC (T1a) at our medical center be-
tween January 1992 and December 2014. The pretreatment di-
agnosis of HGD or early EAC was based on the results of initial or
reinterpreted endoscopic biopsy specimens, cross-sectional
imaging, EUS (if available) and physician assessment. Patients
with suspected T1b or higher tumor (T) stage cancers or those
previously treated with endoscopic ablation or resection, che-
motherapy, radiation, or previous esophageal surgery before
initial endoscopic or surgical procedures at our hospital were
excluded. The following information was extracted from the
medical record: age, gender, race, highest degree of pathologic
dysplasia before EET or surgery, pathology of resected speci-
mens post-EET or surgery, preprocedural endoscopic ultra-
sound (EUS), primary therapeutic modality (EET in the first 12
months of therapy or surgery) performed, and components of
the Charlson Comorbidity Index (CCI). Primary EET was further
subcategorized as PDT, EMR, RFA, cryotherapy alone, or combi-
nation endoscopic therapy based on treatments given during
the initial 12 months of EET.
Development of Barrett’s EET program
At our institution before 1998, esophagectomy was the primary
modality offered for patients requiring definitive therapy for
dysplastic BE or early EAC. Beginning in 1998, we commenced
offering PDT for treatment of HGD and, later, for early cancer.
This was followed in 2001 by the introduction of cap-assisted
and, later, band-ligation assisted EMR. Additional therapies in-
cluding RFA and cryotherapy, alone or in combination with
EMR, were introduced after commercial release (both RFA and
cryotherapy introduced in 2007 at our institution). During the
study period, all endoscopic therapy was performed by one of
six endoscopists specializing in the endoscopic treatment of
Barrett’s esophagus, and esophagectomies were performed by
one of five thoracic surgeons. Decisions on the management
approach for each patient were at the discretion of the treating
and/or consulting physician. A multidisciplinary conference or
protocol-based management at our hospital was not used for
these patients, yet referrals were made between gastroenterol-
ogy and surgery as deemed appropriate by the treating physi-
cian(s).
Pathologic interpretation of all biopsies showing HGD from
outside institutions was confirmed by review from an expert
pathologist at our medical center before initiation of EET. Biop-
sies of patients diagnosed with cancer were not routinely re-
confirmed at our institution. All patients with cancer under-
went cross-sectional imaging to confirm absence of metasta-
ses; EUS was performed selectively in these patients at the dis-
cretion of the treating physician.
Data analysis
Descriptive statistics consisted of means ± standard deviations
or medians with interquartile ranges for continuous variables,
and simple proportions for dichotomous variables. Compari-
sons between treatment groups (EET vs. surgery) without ad-
justment for other factors (single-variable analyses) were per-
formed using independent two-sample t tests for continuous
variables (age, length of Barrett’s esophagus, and Charlson Co-
morbidity Index) and chi-squared tests for categorical variables
(sex, race, pre-therapy EUS, and initial diagnosis). To explore
factors associated with selection of initial treatment (BE-HGD
vs. EAC), multivariable logistic regression analyses were per-
formed. Year of initial treatment and initial pathologic diagno-
sis were included in the model. In order to determine whether
the initial pathologic diagnosis affected the choice of treat-
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ment differently in earlier than in later years, the interaction
between the treatment year and the initial diagnosis was also
included in the model. Additionally, all significant baseline vari-
ables with P<0.25 in the single-variable analyses were included
as covariates. Backwards selection was used to determine the
final model. Since the association between the length of Bar-
rett’s esophagus with treatment in the single-variable analyses
was statistically significant but this variable was not reported in
144 patients, two multivariable logistic regression models were
fit: one excluding and one including length of Barrett’s esopha-
gus. Since the results of both models were similar, only the re-
sults of the full model including length of Barrett’s esophagus
are presented. All P values < 0.05 were considered statistically
significant and 95% confidence limits were reported. Statistical
analyses were performed using SAS 9.4 (Cary, North Carolina,
United States).
Results
At our institution between January 1992 and December 1997,
13 patients underwent primary surgery for BE-HGD or early
EAC. Subsequently, between January 1998 and December
2014, our hospital treated 453 consecutive treatment-naïve pa-
tients with surgical (n = 67) or endoscopic therapy (n=386) for
BE-HGD or T1a EAC (▶Table 1). The EET group was older (67.2
vs. 61.5 years, P<0.0001), had fewer diagnoses of esophageal
adenocarcinoma before therapy initiation (26.4 vs. 64.2%, P<
0.0001), and completed fewer pretreatment EUS exams (57.0
vs. 88.1%, P<0.0001). Among the 309 (68.2%) patients with
available data, mean BE length was shorter in the EET group
compared to the surgery group (4.2 vs. 6.8 cm, P<0.0001).
Mean CCIs were similar between the EET and surgery groups
(3.9 vs. 3.6, P=0.33). Clinical characteristics of surgery patients
from 1992 to 1997 (pre-EET introduction) were similar to sur-
gery patients treated between January 1998 and December
2014 (all P>0.19; data not shown).
▶Table2 demonstrates the endoscopic and surgical treat-
ments employed within the study period. Of the 80 surgeries,
Ivor-Lewis esophagectomy was performed in 45% (n=36),
while transhiatal and three incision approaches were employed
in 25% (n=20) and 28.8% (n=23), respectively. The operation
performed in one patient (1.2%) was unknown. EET (index
▶ Table 1 Baseline characteristics of Endoscopic Eradication Therapy (EET) and Surgery groups for the treatment of BE-HGD or early EAC from 1998
to 2014.
EET (n=386) Surgery (n=67) P value
Male, n (%) 322 (83.4) 55 (82.1) 0.7880
Caucasian, n (%) 379 (99.0) 67 (100.0) 0.4008
Age, mean ± SD, years 67.2 ± 10.8 61.5 ± 10.1 < 0.0001
Pretreatment EUS, n (%) 220 (57.0) 59 (88.1) < 0.0001
Charlson Comorbidity Index (CCI) with age, mean ± SD 3.9 ± 2.3 3.6 ± 2.0 0.33
Pretreatment diagnosis of adenocarcinoma, n (%) 102 (26.4) 43 (64.2) < 0.0001
Length of BE, mean ± SD, cm1 4.2 ± 3.6 6.8 ± 3.4 < 0.0001
Post-therapy adenocarcinoma diagnosis2, n (%) 99 (30.1) 43 (68.3) < 0.0001
Agreement between pre- and post-therapy diagnosis, n (%)3 176 (53.5) 47 (74.6) < 0.0001
BE-HGD, Barrett’s esophagus with high grade dysplasia; EAC, esophageal adenocarcinoma; EUS, endoscopic ultrasound.
1 Data not available for all patients.
2 Post-therapy adenocarcinoma is a pathologic specimen of adenocarcinoma from surgical resection specimen or endoscopic resection specimen/biopsies post-EET
therapy.
3 Comparison between the highest grade of pathology from pre-therapy specimens and post EET biopsies/specimens or surgical resection specimens in the surgical
group.
▶ Table 2 Primary endoscopic (n = 386) or surgical (n = 80) therapy
used during the first 12 months of treatment for 466 patients with
Barrett’s esophagus high grade dysplasia (BE-HGD) or early esopha-
geal adenocarcinoma (EAC) from 1992 to 2014.
Primary endoscopic therapy
– initial 12 months (n=386)
Primary surgical therapy
(n=80)
Single modality therapy, n (%)
▪ PDT alone 45 (11.7%) Ivor Lewis
(transthoracic)
36 (45.0%)
▪ EMR alone 196 (50.8%) Transhiatal 20 (25.0%)
▪ RFA alone 13 (3.4%) Three incision 23 (28.8%)
▪ Cryotherapy
alone
0 (0) Unknown 1 (1.3%)
Combination endoscopic therapy, n (%)
▪ EMR+RFA 83 (21.5%)
▪ EMR+PDT 29 (7.3%)
▪ Other1 20 (5.2%)
PDT, photodynamic therapy; EMR, endoscopic mucosal resection; RFA,
radiofrequency ablation.
1 Other =Combined modalities include: EMR+RFA+Cryotherapy, EMR+PDT
+RFA or EMR+Cryotherapy.
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treatment and all endoscopic therapies in the first 12 months)
included 254 (66%) single modality therapies. Single modality
treatments included PDT in 11.7%, EMR in 50.8%, and RFA in
3.4%. Combination EET was employed in 132 (34%) patients.
▶Table3 presents the type of therapy performed (surgery
or EET), on an annualized basis by pretreatment pathology
(EAC or HGD). As the table illustrates, the highest numbers of
patients treated were in 2007 when 46 patients were treated
and in 2006, 2011, and 2012 when 41 patients were treated.
The table also illustrates a relatively stable proportion of pa-
tients with T1a EAC undergoing surgery during the last 10 years
of the study (2005–2014, with 29.4% of patients with T1a EAC
undergoing surgery during that time). During the same period
of time, however, the number of patients undergoing surgery
for BE-HGD significantly decreased. ▶Fig.1 graphically illus-
trates the distribution of patients undergoing either surgery or
EET on an annualized basis. ▶Fig. 2 demonstrates the annual
percentage contribution of single or combination modality
endoscopic treatments to the total EET utilization. Overall, pa-
tients underwent a median of 2 (IQR 1–3) EET procedures in
the initial 12 months of endoscopic therapy. PDT was the first
EET modality adopted and was incorporated in all EET cases in
1998 and 1999 but was not used after 2007. EMR was later in-
troduced with significant utilization starting in 2001, and in-
creasing in use either as a sole modality or combination modal-
ity thereafter. RFA was first introduced in 2007, predominantly
as a combination therapy. Since 2007, the use of EMR and RFA
for combination therapy has risen, and in the latter few years of
the study, was used in over half of the EET cases.
▶ Table 3 Frequency of primary endoscopic (n = 386) or surgical (n = 80) therapy used by year for 466 consecutive patients from 1992 to 2014 with
BE-HGD or T1a EAC.
Year T1a HGD All patients
Surgery EET Total Surgery EET Total Total
n % n % n n % n % n n
1992 1 100.0 0 0.0 1 0 – 0 – 0 1
1993 0 – 0 – 0 1 100.0 0 0.0 1 1
1994 0 – 0 – 0 0 – 0 – 0 0
1995 2 100.0 0 0.0 2 1 100.0 0 0.0 1 3
1996 2 100.0 0 0.0 2 2 100.0 0 0.0 2 4
1997 2 100.0 0 0.0 2 2 100.0 0 0.0 2 4
1998 0 0.0 3 100.0 3 2 22.2 7 77.8 9 12
1999 1 25.0 3 75.0 4 2 28.6 5 71.4 7 11
2000 2 40.0 3 60.0 5 3 15.8 16 84.2 19 24
2001 0 0.0 5 100.0 5 1 20.0 4 80.0 5 10
2002 0 0.0 5 100.0 5 2 25.0 6 75.0 8 13
2003 3 60.0 2 40.0 5 1 11.1 8 88.9 9 14
2004 5 55.6 4 44.4 9 3 20.0 12 80.0 15 24
2005 3 16.7 15 83.3 18 1 6.3 15 93.7 16 34
2006 0 0.0 8 100.0 8 2 6.1 31 93.9 33 41
2007 1 5.9 16 94.1 17 0 0.0 29 100.0 29 46
2008 3 25.0 9 75.0 12 2 9.5 19 90.5 21 33
2009 3 37.5 5 62.5 8 1 5.9 16 94.1 17 25
2010 8 66.7 4 33.3 12 0 0.0 25 100.0 25 37
2011 5 55.6 4 44.4 9 3 9.4 29 90.6 32 41
2012 4 30.8 9 69.2 13 1 3.6 27 96.4 28 41
2013 3 37.5 5 62.5 8 0 0.0 12 100.0 12 20
2014 2 50.0 2 50.0 4 0 0.0 18 100.0 18 22
EET, endoscopic eradication therapy; BE-HGD, Barrett’s esophagus with high grade dysplasia.
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Single-variable analyses of patients undergoing EET (n =386)
or surgery (n =67) from 1998 to 2014 showed only age, use of
EUS, and length of Barrett’s esophagus were significant (P<
0.25). Therefore, the multivariable model included these three
variables as well as the initial diagnosis (BE-HGD vs. EAC), year
of the initial therapeutic procedure, and the interaction term
between year of the procedure and initial diagnosis. The multi-
variable model indicated that older patients were more likely to
undergo EET (P=0.0009). The odds of EET compared to surgery
increased by 1.22, CI (1.09–1.37) for every 3-year increase in
age; 1.39, CI (1.15–1.69) for every 5-year increase in age; and
1.94, CI (1.31–2.86) for every 10-year increase in age. Shorter
length of BE was significantly associated with EET (P <0.0001).
For every 1 cm decrease in length of BE, the odds of undergoing
EET compared to surgery increased by 1.21, CI (1.10–1.33).
The year the exam was performed affected the selected proce-
dure differently by initial diagnosis (P=0.0182). The diagnosis
of EAC did not increase the utility of EET compared to surgery
as time progressed (P=0.8165); however, patients initially di-
agnosed with BE-HGD had higher odds of receiving EET com-
pared to surgery for each subsequent year (P=0.0054). The
odds of undergoing EET increased by 1.32 (CI 1.09–1.62) for
each subsequent year (▶Table4).
Discussion
EET has been incorporated into the National Comprehensive
Cancer Network (NCCN) guidelines as a primary modality for
the management of early (Tis, T1a) esophageal malignancy at
low risk for lymph node metastases [19]. However, about 25
years ago, endoscopic treatment was not generally considered
to be a first line treatment for these patients. As with any new
modality, incorporation of novel technology and treatment op-
tions into consensus guidelines requires demonstration of
equivalent or superior but safe outcomes to currently available
techniques. A meta-analysis of seven retrospective cohort stud-
ies published between 2003 and 2011 showed that, compared
to esophagectomy, EET for Barrett’s esophagus with HGD or
T1a EAC is associated with fewer major adverse events and sim-
ilar rates of neoplastic remission and 1-year, 3-year, and 5-year
survival [11–13, 16, 22–25]. This efficacy is reflected in the
2012 American Society for Gastrointestinal Endoscopy (ASGE)
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▶ Fig. 1 Primary endoscopic (n =386) or surgical (n =80) therapy used during the first 12 months of treatment for 466 patients with Barrett’s
Esophagus with High Grade Dysplasia (BE-HGD) or early esophageal adenocarcinoma (EAC) from 1992 to 2014, displayed on an annualized
basis according to therapy performed and underlying pathology.
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guidelines for EET of Barrett’s associated dysplasia which con-
sidered PDT, RFA, cryotherapy, EMR, and endoscopic submuco-
sal dissection (ESD) as viable treatment options in these pa-
tients, and EMR or ESD for nodular dysplasia [26]. These options
in patients with early cancer were different from the 2003
guidelines in the management of esophageal cancer, which re-
commended surgical resection for all patients with early esoph-
ageal adenocarcinoma who were surgical candidates [27]. In an
updated 2013 ASGE publication on the same topic, multiple
endoscopic treatment modalities including EMR, ESD, PDT,
and RFA were included for management options of early esoph-
ageal adenocarcinoma [28].
Similar to the evidence-based evolution of guidelines, our
group’s therapeutic offerings for these patients have changed.
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▶ Fig. 2 Annual percentage contribution of single or combination modality endoscopic treatments to the total EET utilization from 1998 to
2014.
▶ Table 4 Results of Multivariable Logistic Regression analyses comparing factors associated with receiving Endoscopic Eradication Therapy (EET) vs.
Surgery from 1998 to 2014.
EET vs. Surgery
Odds Ratio (95% CI) Relative Risk (95% CI) P value
Age 0.0009
▪ 3-year increase 1.22 (1.09, 1.37) 1.18 (1.07, 1.29)
▪ 5-year increase 1.39 (1.15, 1.69) 1.30 (1.12, 1.51)
▪ 10-year increase 1.94 (1.31, 2.86) 1.67 (1.24, 2.17)
EUS not performed 4.78 (1.24, 18.41) 2.90 (1.19, 4.62) 0.0230
Length of BE (1 cm decrease) 1.21 (1.10, 1.33) 1.17 (1.08, 1.26) < 0.0001
Initial diagnosis by year 0.0182
▪ Year for BE-HGD 1.32 (1.09, 1.62) 1.25 (1.07, 1.46) 0.0054
▪ Year for EAC 0.98 (0.85, 1.14) 0.98 (0.87, 1.11) 0.8165
BE-HGD, Barrett’s esophagus with high grade dysplasia; EAC, esophageal adenocarcinoma; EUS, endoscopic ultrasound.
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Our study highlights the evolution and use of different endo-
scopic modalities for EET at our hospital following the institu-
tion of an EET program in 1998. Before 1998, esophagectomy
was the only modality offered at our hospital for management
of dysplastic BE or early EAC. Our EET program started in 1998
with PDT monotherapy for BE-HGD and eventually progressed
to offer EMR and multimodal therapy for these patients. While
the use of PDTwaned, EMR was gradually adopted as the princi-
pal single modality therapy and was eventually used in combi-
nation with RFA for the majority of patients.
In the current study, EET patients were older, had fewer pre-
procedure diagnoses of esophageal adenocarcinoma, comple-
ted fewer pretreatment EUS exams, and had a shorter BE length
compared to the surgery group. The more frequent use of EUS
in the surgery group is likely explained by the more frequent di-
agnosis of cancer in this population and the decreasing use over
time of EUS in patients diagnosed with HGD alone. Multivari-
able regression analysis found that patients who were older
and had BE-HGD were more likely to undergo EET compared to
surgery as study time progressed. Patients with shorter BE
length were also more likely to undergo EET; however, the diag-
nosis of cancer did not affect the choice of treatment received.
These findings demonstrate increased use of EET over time at
our hospital in patients with BE-HGD but not with suspected
T1a EAC.
Although other smaller studies have described institutional
approaches to BE-HGD and early EAC over time [14, 29], this is
the first study to systematically review surgical and endoscopic
management at a single institution over two decades. The cur-
rent study highlights the development of our EET program and
investigates several factors which may have impacted the use
of EET or surgery for these patients over a 22-year period. How-
ever, our study does have some limitations. First, although pa-
tients evaluated were chosen from two prospective databases,
it is possible that some receiving surgery or endoscopy during
the study period were not enrolled. Second, our study did not
use a multidisciplinary clinic or protocol to triage these patients
to surgical or endoscopic therapy. Factors such as patient pre-
ferences, referral patterns, and referring provider recommen-
dations which may have influenced management decisions
were not evaluated in the current study.
In conclusion, this single-center retrospective study of the
treatment-naïve patient with BE-HGD or early EAC from 1992
to 2014 found that patients who were older, had a pretreat-
ment diagnosis of HGD, and shorter BE length were more likely
to undergo EET compared to surgery as study time progressed.
Pretreatment diagnosis of T1a esophageal cancer did not affect
the choice of treatment received.
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